The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity.
Blood pressure
Dose intensity
Hypertension
Lenvatinib
Side effect
Thyroid carcinoma
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
29 Nov 2023
29 Nov 2023
Historique:
received:
15
04
2023
accepted:
06
11
2023
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
28
11
2023
Statut:
epublish
Résumé
Lenvatinib (LEN) is a multikinase inhibitor that strongly inhibits tyrosine kinase receptors, especially VEGFR-2, which can cause hypertension, as well as strong tumor shrinkage. Though control of any side effects (SEs) is important for maintaining dose intensity (DI), hypertension is particularly important, because blood pressure (BP) can change quickly and respond to LEN administration and withdrawal, and it can be controlled with antihypertensive medications. Focusing on the early phase of treatment, the effect of BP 8 weeks after LEN initiation (BP The subjects were 85 thyroid cancer patients who started LEN at 24 mg/day and continued for ≥8 weeks. The BP at the start of LEN (BP Median (range) systolic BP changed significantly from BP LEN can increase BP by 20 mmHg at 8 weeks even with intensive antihypertensive management. Baseline antihypertensive treatment and BP
Identifiants
pubmed: 38017341
doi: 10.1007/s00520-023-08163-x
pii: 10.1007/s00520-023-08163-x
doi:
Substances chimiques
Antihypertensive Agents
0
lenvatinib
EE083865G2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
729Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Arima H, Kiyohara Y, Kato I, Tanizaki Y, Kubo M, Iwamoto H, Tanaka K, Abe I, Fujishima M (2002) Alcohol reduces insulin-hypertension relationship in a general population: the Hisayama study. J Clin Epidemiol 55:863–869
doi: 10.1016/S0895-4356(02)00441-9
pubmed: 12393073
Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH (2022) A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab 107:776–787
doi: 10.1210/clinem/dgab731
pubmed: 34664662
Capdevila J, Newbold K, Licitra L, Popovtzer A, Moreso F, Zamorano J, Kreissl M, Aller J, Grande E (2018) Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treat Rev 69:164–176
doi: 10.1016/j.ctrv.2018.06.019
pubmed: 30032061
Colombo C, Ceruti D, De Leo S, Bilo G, Trevisan M, Giancola N, Moneta C, Parati G, Persani L, Fugazzola L (2023) Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm. Eur Thyroid J.:12
Fukuda N, Toda K, Wang X, Ohmoto A, Hayashi N, Urasaki T, Sato Y, Nakano K, Ono M, Tomomatsu J, Mitani H, Takahashi S (2021) Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. Endocr J 68:639–647
doi: 10.1507/endocrj.EJ20-0754
pubmed: 33504716
Gupta A, Jarzab B, Capdevila J, Shumaker R, Hussein Z (2016) Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol 81:1124–1133
doi: 10.1111/bcp.12907
pubmed: 26879594
pmcid: 4876185
Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI (2017) Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 56:121–128
doi: 10.1007/s12020-017-1233-5
pubmed: 28155175
pmcid: 5368192
Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 46:439–448
doi: 10.1016/j.ejca.2009.11.001
pubmed: 20006922
Kario K, Robbins J, Jeffers BW (2013) Titration of amlodipine to higher doses: a comparison of Asian and Western experience. Vasc Health Risk Manag 9:695–701
doi: 10.2147/VHRM.S50077
pubmed: 24235839
pmcid: 3821790
Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y, Wirth L, Robinson B, Sherman S, Suzuki T, Fujino K, Gupta A, Hayato S, Tahara M (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106:1714–1721
doi: 10.1111/cas.12826
pubmed: 26426092
pmcid: 4714672
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173
doi: 10.1016/S0140-6736(18)30207-1
pubmed: 29433850
Makker V, Colombo N, Casado Herraez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD et al (2022) Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med 386:437–448
doi: 10.1056/NEJMoa2108330
pubmed: 35045221
Masaki C, Sugino K, Kobayashi S, Akaishi J, Hames KY, Tomoda C, Suzuki A, Matsuzu K, Uruno T, Ohkuwa K, Kitagawa W, Nagahama M, Ito K (2020) Urinalysis by combination of the dipstick test and urine protein-creatinine ratio (UPCR) assessment can prevent unnecessary lenvatinib interruption in patients with thyroid cancer Int. J Clin Oncol 25:1278–1284
Masaki C, Sugino K, Saito N, Saito Y, Tanaka T, Ogimi Y, Maeda T, Osaku T, Akaishi J, Hames KY, Tomoda C, Suzuki A, Matsuzu K, Uruno T, Ohkuwa K, Kitagawa W, Nagahama M, Takami H, Ito K (2017) Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma. Endocr J 64:819–826
doi: 10.1507/endocrj.EJ17-0104
pubmed: 28659544
Masaki C, Sugino K, Saito N, Akaishi J, Hames KY, Tomoda SA, Matsuzu K, Uruno T, Ohkuwa K, Kitagawa W, Nagahama M, Ito K (2020) Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. Thyroid 30(2):214–221
doi: 10.1089/thy.2019.0221
pubmed: 31854270
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, Kopyltsov E, Mendez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289–1300
doi: 10.1056/NEJMoa2035716
pubmed: 33616314
Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, Wakui H, Sasaki T, Yusa W, Fujino K, Tamura T (2015) A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 76:1153–1161
doi: 10.1007/s00280-015-2899-0
pubmed: 26530955
pmcid: 4648947
Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M (2016) Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab 101:4103–4109
doi: 10.1210/jc.2015-3989
pubmed: 27548104
pmcid: 5095235
Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N (2020) Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 21:843–850
doi: 10.1016/S1470-2045(20)30162-5
pubmed: 32502444
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621–630
doi: 10.1056/NEJMoa1406470
pubmed: 25671254
Stjepanovic N, Capdevila J (2014) Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Biologics 8:129–139
pubmed: 24748771
Takahashi S, Tahara M, Ito K, Tori M, Kiyota N, Yoshida K, Sakata Y, Yoshida A (2020) Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan. Adv Ther 37:3850–3862
doi: 10.1007/s12325-020-01433-8
pubmed: 32676927
pmcid: 7444395
Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747
doi: 10.1155/2014/638747
pubmed: 25295214
pmcid: 4177084
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE (2020) 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension 75:1334–1357
doi: 10.1161/HYPERTENSIONAHA.120.15026
pubmed: 32370572
Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M (2018) Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer 124:2365–2372
doi: 10.1002/cncr.31344
pubmed: 29656442
Wu S, Keresztes RS (2011) Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Invest 29:460–471
pubmed: 21740083
Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T (2011) Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 17:2528–2537
doi: 10.1158/1078-0432.CCR-10-2638
pubmed: 21372218
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H (2020) REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 55:113–122
doi: 10.1007/s00535-019-01642-1
pubmed: 31720835
Yang X, Guo N, Gao X, Liang J, Fan X, Zhao Y (2022) Meta-analysis of TSH suppression therapy and the risk of cardiovascular events after thyroid cancer surgery. Front Endocrinol (Lausanne) 13:991876
doi: 10.3389/fendo.2022.991876
pubmed: 36619576
Zenda S, Uchitomi Y, Morita T, Yamaguchi T, Inoue A (2021) Establishment of a research policy for supportive and palliative care in Japan. Jpn J Clin Oncol 51:538–543
doi: 10.1093/jjco/hyab008
pubmed: 33561254
pmcid: 8129624